Acumen Pharmaceuticals

Yahoo Finance • 30 days ago

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

NEWTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of... Full story

Yahoo Finance • last month

Acumen Pharmaceuticals stock maintains Buy rating at BTIG on promising Alzheimer's drug

Investing.com - BTIG has reiterated its Buy rating and $11.00 price target on Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), citing the company’s de-risked subcutaneous clinical candidate Sabirnetug for Alzheimer’s disease treatment. Accordin... Full story

Yahoo Finance • 2 months ago

Bullish Two Hundred Day Moving Average Cross - XHB

In trading on Monday, shares of the SPDR S&P Homebuilders ETF (Symbol: XHB) crossed above their 200 day moving average of $104.55, changing hands as high as $104.98 per share. SPDR S&P Homebuilders shares are currently trading up about 0.... Full story

Yahoo Finance • 2 months ago

Catalyst Watch: Alphabet earnings, McGraw Hill IPO, Trump talks AI, and more robotaxi buzz

[Close up of buildings in Wall Street] Alphotographic Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MON... Full story

Yahoo Finance • 2 months ago

Acumen, JCR Pharma Join To Develop Oligomer-targeted Enhanced Brain Delivery Therapy For Alzheimers

(RTTNews) - Acumen Pharmaceuticals (ABOS) announced a collaboration, option and license agreement with JCR Pharmaceuticals to develop an oligomer-targeted Enhanced Brain Delivery therapy for Alzheimers disease. JCR is a global specialty ph... Full story

Yahoo Finance • 3 months ago

Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer’s Association International Conference (AAIC®) 2025

NEWTON, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment... Full story

Yahoo Finance • 5 months ago

Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

NEWTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta ol... Full story

Yahoo Finance • 6 months ago

Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting

NEWTON, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the tre... Full story

Yahoo Finance • 6 months ago

Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer’s

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Today's Marketplace (TMP) is proud to announce a featured interview with Acumen Pharmaceuticals(NASDAQ: ABOS) CEO Daniel O’Connell and Jessica Clark, DNP, RN, Dean of the College of Nursing at... Full story

Yahoo Finance • 6 months ago

Acumen Pharmaceuticals to Present During International Conference on Alzheimer’s and Parkinson’s Diseases 2025 and American Academy of Neurology Annual Meeting

NEWTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment... Full story

Yahoo Finance • 2 years ago

Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures

Provides additional capital to support development of a subcutaneous formulation of ACU193 and general corporate purposes$30 million drawn down at loan closing CHARLOTTESVILLE, Va., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceutica... Full story

Yahoo Finance • 2 years ago

Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights

Initiation of a Phase 2 study, ALTITUDE-AD, to investigate ACU193 for the treatment of early Alzheimer’s disease expected in the first half of 2024, following positive FDA interaction in October 2023 Announced global collaboration and lic... Full story

Yahoo Finance • 2 years ago

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

CHARLOTTESVILLE, VA. and INDIANAPOLIS, IN., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta... Full story

Yahoo Finance • 2 years ago

Acumen Pharmaceuticals to Report Third Quarter Financial Results on November 13, 2023

CHARLOTTESVILLE, VA. and INDIANAPOLIS, IN., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets... Full story

Yahoo Finance • 2 years ago

Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE® Technology

CHARLOTTESVILLE, VA. and INDIANAPOLIS, IN., Nov. 06, 2023 (GLOBE NEWSWIRE) --  Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that target... Full story

Yahoo Finance • 2 years ago

Acumen Pharmaceuticals to Participate in the UBS Biopharma Conference

CHARLOTTESVILLE, Va., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the trea... Full story

Yahoo Finance • 2 years ago

Acumen Pharmaceuticals Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen and Safety Findings for ACU193 in Early Alzheimer’s Disease at the 16th Annual Clinical Trials on Alzheimer’s Disease

- Acumen presented data exploring target engagement modeling of ACU193, the first clinical-stage amyloid beta oligomer (AβO)-targeting antibody, to inform dose selection, plus further analyses of dose-related amyloid plaque reduction and c... Full story

Yahoo Finance • 2 years ago

Acumen Pharmaceuticals to Present Deeper Insights from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s During Symposium at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD)

Expanded analyses from robust Phase 1 INTERCEPT-AD trial exploring novel target engagement (dose-related), amyloid plaque reduction, and ARIA levels observed with ACU193 administration to be included in a symposium on Friday, October 27 N... Full story

Yahoo Finance • 2 years ago

Acumen Pharmaceuticals to Participate in the Cantor Global Healthcare Conference

CHARLOTTESVILLE, Va. and CARMEL, Ind., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta olig... Full story

Yahoo Finance • 2 years ago

Acumen Pharmaceuticals to Participate in the H.C. Wainwright Annual Global Investment Conference

CHARLOTTESVILLE, Va. and CARMEL, Ind., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta olig... Full story